Derived Stem Cells Articles & Analysis
46 news found
Creative Biostructure, a leading provider of structural biology services and products, is pleased to announce the expansion of its exosome product line to include a broader range of exosomes isolated from various stem cell lines. This strategic enhancement aims to support and accelerate research in regenerative medicine, drug delivery, and related fields by ...
Our lead product is 3D cardiac engineered heart tissues (EHTs) fabricated from human induced pluripotent stem cell (iPSC) derived cardiomyocytes. Applying induced pluripotent stem cell (iPSC) technology, patient-cell derived 3D micro tissues exhibiting hereditary cardiac diseases ...
(IVS) is a leading developer of proprietary human 3D cell/tissue culture models for highly-predictive, multi-parameter phenotypic assays both in pharmacology safety & discovery screening and in personalized and regenerative medicine. ...
A third key strategic element to enhance sales growth are the acquired platform companies BlueRock Therapeutics (BlueRock), Asklepios Biopharmaceutical (AskBio) and Vividion Therapeutics (Vividion), with their industry-leading scientific innovation which have already successfully diversified and strengthened Bayer’s pipeline. BlueRock, a pioneer in stem ...
ByBayer AG
Additionally, the designation validates our belief in the potential of our stem cell regenerative PEDF-Derived Short Peptide (PDSP), which underpins several products in our pipeline, and has the potential to be effective in multiple therapy areas and ...
” BRM421 is a novel, first-in-class regenerative peptide therapy which, if successful, could offer patients full relief of symptoms plus repair the damage to the cornea. BRM421 is derived from BRIM’s proprietary, stem cell regenerative PEDF-derived Short Peptides (PDSPs), which can also be applied across multiple ...
Human induced pluripotent stem cell-derived beta-cells for drug and toxicity ...
BRM421 is a novel, first-in-class regenerative peptide therapy which, if successful, could offer patients complete relief from dry eye symptoms by stimulating the proliferation and differentiation of stem cells to repair damage to the cornea. BRM421 was developed using BRIM’s proprietary stem cell regenerative Pigment ...
The patent broadens the Company’s intellectual property coverage of genetically engineered innate immune cells beyond gamma-delta T cells to include NK cells. Like gamma-delta T cells, NK cells respond directly to cellular stress and have shown promise in cellular therapy clinical trials. ...
About ImmCelz ImmCelz®, which is protected by trade secrets and published U.S. patents, utilizes adult stem cells derived from qualified donors to endow specific properties to the patient's immune cells. ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell-derived, fully differentiated pancreatic islet cell replacement therapy, have been accepted for presentation ...
BRM421 is based on BRIM’s proprietary stem cell regenerative Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) technology platform, which underpins several products in its pipeline and has the potential to be effective in multiple therapy areas and indications. The functional domain of PEDF chosen to ...
” First Quarter Clinical and Regulatory Updates CYNK-001 for the Treatment of AML and GBM: CYNK-001 is Celularity’s unmodified cryopreserved human placental hematopoietic stem cell-derived NK cell therapy candidate that is enriched with CD56+/CD3- NK cells and expanded from human placental CD34+ ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia. ...
Follow up in vivo studies in matched patient-derived xenograft (PDX) models were also performed by Crown Bioscience. ...
About ImmCelz ImmCelz®, which is protected by trade secrets and published U.S. patents, utilizes adult stem cells derived from qualified donors to endow specific properties to the patient's immune cells. After the patient's harvested cells are incubated with the Company's cell-free ...
TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the launch of The Stem Cell SpaceShot Grant, a $100,000 research funding in the field of stem ...
Melissa, a world-renowned expert in iPSC-derived cell therapies, will reinforce our U.S. network and help us steer our programs toward clinical trials. ...
Min brings to Longeveron over a decade of pharma and biotech clinical development experience. This includes work on novel cell therapy, leading R&D and clinical teams, and advancing regulatory engagements with the U.S. ...
ImmCelz®, which is protected by trade secrets and published U.S. patents, utilizes adult stem cells derived from qualified donors to endow specific properties to the patient's immune cells. After the patient's harvested cells are incubated with the Company's cell-free reprogramming ...